- Home
- MUA vs CTMX Comparison
MUA vs CTMX Comparison
Compare MUA & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MUA | CTMX |
|---|---|---|
| Founded | N/A | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 666.0M | 716.9M |
| IPO Year | 1994 | 2015 |
Fundamental Metrics
Financial Performance| Metric | MUA | CTMX |
|---|---|---|
| Price | $9.77 | $2.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $12.25 |
| AVG Volume (30 Days) | 323.3K | ★ 3.3M |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $76,201,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.24 |
| P/E Ratio | ★ N/A | $22.58 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.13 | $2.16 |
| 52 Week High | $11.26 | $8.21 |
Technical Indicators
Market Signals| Indicator | MUA | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 55.65 | 36.13 |
| Support Level | $9.62 | N/A |
| Resistance Level | $9.76 | $2.61 |
| Average True Range (ATR) | 0.16 | 0.16 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 56.78 | 5.32 |
Price Performance
Historical ComparisonAbout MUA Blackrock MuniAssets Fund Inc
Blackrock Muniassets Fund Inc is a closed-end fund. Its objective is to provide high current income exempt from U.S. federal income taxes by investing in a portfolio of medium- to lower-grade or unrated municipal obligations. The Fund invests more of its total assets in municipal bonds.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.